RE:Anakinra Attenuates Glioblastoma AggressivenessBTI has xB3-Anakinra that could be used with Midatech's glioblastoma drug. xB3 could be used with Midatech's lead drug. BTI's xB3-Avastin could also complement Midatech's glioblastoma drug. Rathjen's other company is involved with CAR-T and CAR-T brain delivery may be achieved with Midatech's delivery system. CAR-T and Anakinra could also benefit together.
----
"Despite these mediocre responses, HER2-directed CAR-T therapy shows promise for glioblastoma considering the area’s high unmet need, lack of available treatment options after chemotherapy and radiotherapy, and a low threshold of clinically acceptable toxicity due to the acute lethality of the disease. This is reflected in the ongoing clinical trials data; GlobalData has identified 12 ongoing clinical trials for HER2-directed CAR-T therapy, five of which are in breast cancer and seven in brain tumors, despite the breast cancer market being one of the most lucrative oncology markets."